down arrow

180 Life Sciences Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US68236V2034
USD
11.79
1.15 (10.81%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

11.1611.82

52 Week

6.58174.60
Valuation
Technical
Day's Volume

CASH

547.31 k

Shareholding (Mar 2025)

FII

1.59%

Held by 7 FIIs

DII

97.71%

Held by 1 DIIs

Promoter

0.00%

How big is 180 Life Sciences Corp.?

22-Jun-2025

As of Jun 18, 180 Life Sciences Corp. has a market capitalization of 5.29 million, with net sales of 0.00 million and a net profit of -7.47 million. Shareholder's funds were 9.25 million, and total assets amounted to 33.51 million.

As of Jun 18, 180 Life Sciences Corp. has a market capitalization of 5.29 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters and a net profit of -7.47 million.<BR><BR>As of Dec 24, the shareholder's funds were 9.25 million, and the total assets amounted to 33.51 million.

Read More

What does 180 Life Sciences Corp. do?

22-Jun-2025

180 Life Sciences Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $5.29 million. Key metrics include a negative P/E ratio, no dividend yield, and a price-to-book ratio of 0.69.

Overview:<BR>180 Life Sciences Corp. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 5.29 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.46<BR>- Return on Equity: -42.26%<BR>- Price to Book: 0.69<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

Read More

Is 180 Life Sciences Corp. technically bullish or bearish?

20-Sep-2025

As of August 28, 2025, 180 Life Sciences Corp. shows a mildly bullish trend with mixed signals, having gained 4.15% over the past week but down 66.13% in the last month, while year-to-date it is up 37.91%, outperforming the S&P 500's 12.22%.

As of 28 August 2025, the technical trend for 180 Life Sciences Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages and a bullish KST on the weekly timeframe. However, the weekly MACD is mildly bearish, and the monthly RSI indicates bearish momentum. The Bollinger Bands are mildly bullish on both weekly and monthly charts, suggesting some upward potential. <BR><BR>In terms of performance, the stock has returned 4.15% over the past week compared to the S&P 500's 1.05%, but it has seen a significant decline of 66.13% over the past month against the S&P's 2.33%. Year-to-date, the stock is up 37.91%, outperforming the S&P 500's 12.22%. Overall, while there are some bullish indicators, the mixed signals suggest caution.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of -1.00% and Operating profit at -329.35% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -6.60
2

The company has declared negative results in Mar'2025 after 5 consecutive positive quarters

3

Risky - Negative EBITDA

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 401 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.15

stock-summary
Return on Equity

-114.07%

stock-summary
Price to Book

74.57

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-53.21%
0%
-53.21%
6 Months
13.37%
0%
13.37%
1 Year
-48.74%
0%
-48.74%
2 Years
-78.07%
0%
-78.07%
3 Years
-99.25%
0%
-99.25%
4 Years
-99.91%
0%
-99.91%
5 Years
-99.88%
0%
-99.88%

180 Life Sciences Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is 180 Life Sciences Corp. technically bullish or bearish?

As of 28 August 2025, the technical trend for 180 Life Sciences Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages and a bullish KST on the weekly timeframe. However, the weekly MACD is mildly bearish, and the monthly RSI indicates bearish momentum. The Bollinger Bands are mildly bullish on both weekly and monthly charts, suggesting some upward potential. In terms of performance, the stock has returned 4.15% over the past week compared to the S&P 500's 1.05%, but it has seen a significant decline of 66.13% over the past month against the S&P's 2.33%. Year-to-date, the stock is up 37.91%, outperforming the S&P 500's 12.22%. Overall, while there are some bullish indicators, the mixed signals suggest caution....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-1.00%
EBIT Growth (5y)
-329.35%
EBIT to Interest (avg)
-6.60
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
0.01
Tax Ratio
4.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.38%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.77
EV to EBIT
-0.37
EV to EBITDA
-0.38
EV to Capital Employed
0.57
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-153.04%
ROE (Latest)
-42.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 3 Schemes (0.7%)

Foreign Institutions

Held by 7 Foreign Institutions (1.59%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 100.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.70",
          "val2": "-1.80",
          "chgp": "5.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 68.84% vs 48.58% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.30",
          "val2": "-13.40",
          "chgp": "52.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.90",
          "val2": "-8.80",
          "chgp": "67.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.20",
          "val2": "-19.90",
          "chgp": "68.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.70
-1.80
5.56%
Interest
0.00
0.00
Exceptional Items
0.00
0.20
-100.00%
Consolidate Net Profit
-1.70
0.00
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 0.00% vs 100.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.30
-13.40
52.99%
Interest
0.10
0.00
Exceptional Items
-2.90
-8.80
67.05%
Consolidate Net Profit
-6.20
-19.90
68.84%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 68.84% vs 48.58% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About 180 Life Sciences Corp. stock-summary
stock-summary
180 Life Sciences Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."